Dr. John Cush RheumNow
2 years 7 months ago
Prior RCT showed continuous NSAID slowed XRay progress in SpA. New 2 yr RCT of 109 pts shows when celecoxib added to TNFi Rx (golimumab) in high risk SpA there was no added Xray benefits (by mSASSS). https://t.co/i0KTPAaLFz https://t.co/dB2Q3PHhcK
Dr. John Cush RheumNow
2 years 7 months ago
You can still attend RheumNow Live!
Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis.
https://t.co/iklCv4JouH
Register: https://t.co/ODaF07gP5s https://t.co/ToTpyQK4r4
Dr. John Cush RheumNow
2 years 7 months ago
Sodium Channels, Carbemazepine and Osteoarthritis Progression
A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.
https://t.co/P6Ef6N8eDC https://t.co/ASc34G5TBX
Dr. John Cush RheumNow
2 years 7 months ago
Increased CV Comorbidity in Dermatomyositis
A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,
https://t.co/8OhcLL5f6Y https://t.co/zVmyrx2DdI
Dr. John Cush RheumNow
2 years 7 months ago
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away!
Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights.
https://t.co/ny6R6QBq0j https://t.co/slHPPOQIDi
Dr. John Cush RheumNow
2 years 7 months ago
US Retrospective cohort study at 29 academic centers of 2428 adults hospitalized, of whom 550 (23%) had a diagnostic error (Pt assessment or testing) contributed to harm or death in 18%. 1863 pts died, w/ 6.6% having diagnostic error that contributed https://t.co/AN1sQt5A1h https://t.co/ZcDbxcoVWJ
Dr. John Cush RheumNow
2 years 7 months ago
Burnout! A cross-sectional study of 3024 US physicians, 60% took <=3 weeks of vacation per year, and 70.4% worked while on vacation on a typical vacation day; both findings were associated with higher rates of burnout. https://t.co/M3iFxKNoSE https://t.co/bc6WBkg7Ff
Dr. John Cush RheumNow
2 years 7 months ago
While NSAID use has been assoc w/ lower risk of cancers (CNS, breast, esophageal, gastric, head & neck, hepatocellular, cholangiocarcinoma, colorectal, endometrial, lung, ovary, prostate, pancreatic); NSAIDs should not be used to prevent cancers https://t.co/YcsU7x7iy0 https://t.co/QJjHqjnuEo
Dr. John Cush RheumNow
2 years 7 months ago
Retrospective study of 170 #RA on TNFi (Inflx 53%, ADA 28%, CZP 19%). RF, CCP, Drug levels, anti-Drug Abs done.@6 mos HI baseline RF linked to lower drug levels for IFX & ADA; but not CZP. IFX/ADA Hi-RF pts had more dropouts vs CZP (80%/75%/33%, p=0.002) https://t.co/AIgJNkzcWu https://t.co/pQmfmLoFwe
Findings from a population based cross-sectional study suggests that while up to 20% of patients have antibodies to tick-borne exposures, only a minority reported musculoskeletal symptoms.
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
Non-pharmacological treatments for OA are as important and impactful at improving pain, function and quality of life in OA. These EULAR recommendations were originally published in 2013.
